• Special Issue Topic

    The Urgent Need for New Hypotheses to Develop Effective Therapeutic Tools Against Alzheimer's Disease

    Submission Deadline: June 30, 2024

    Guest Editor

    Prof. Rafael Franco E-Mail

    Professor of Biochemistry and Molecular Biology, Universidad de Barcelona, Barcelona, Spain

    Research Keywords: G protein coupled receptors (GPCR); Alzheimer's Disease; Parkinson's disease; neuroprotection; microglia; neurodegeneration

    About the Special Issue

    The amyloid hypothesis has not led to any effective therapeutic intervention for the management of Alzheimer's disease (AD). The controversy over whether protein aggregation is the cause or consequence of AD is no longer relevant. The urgent thing is to formulate hypotheses that can explain why neurons begin to suffer and finally die and cause the disease. This special issue seeks strong hypotheses as well as novel contributions focused primarily on the patient and taking data from patients, ranging from the type of profession to the events, emotional or clinical, surrounding the date of onset. Welcome are also ideas on novel public Health studies to correlate life style, neurological and non-neurological diseases, medication, etc., with the onset and progression rate of the disease. The special issue is open both to novel hypotheses, based on scientific criteria, and to studies in patients and controls, regardless of whether they are carried out in a small number of individuals.

    Keywords: Alzheimer’s disease; neuroprotection; public health; epidemiological studies; neuronal death; neuronal survival; synaptic plasticity

    Call for Papers

    Published Articles

    Open Access
    “Vitaction” deficiency: a possible root cause for multiple lifestyle disorders including Alzheimer’s disease
    Behavioural environment and behavioural responses of an individual are known to affect multiple aspects of physiology including neuroendocrine and growth factor signalling, angiogenesis, stem cell d [...] Read more.
    Milind Watve, Ashwini Keskar Sardeshmukh
    Published: April 07, 2024 Explor Neuroprot Ther. 2024;4:108–118
    DOI: https://doi.org/10.37349/ent.2024.00074
    Times Cited: 0
    Open Access
    Original Article
    Cannabinoid CB2 receptor ligands disrupt the sequential regulation of p-MEK1/2 to p-ERK1/2 in mouse brain cortex
    Aim The sequential phosphorylation of mitogen-activated protein (MAP) kinases MEK-ERK is the most relevant cellular signaling pathway. This study quantified the parallel in vivo regulation of bra [...] Read more.
    Glòria Salort ... Jesús A. García-Sevilla
    Published: October 24, 2023 Explor Neuroprot Ther. 2023;3:258–267
    DOI: https://doi.org/10.37349/ent.2023.00050
    Times Cited: 0
    Open Access
    Original Article
    Alzheimer’s disease detection from magnetic resonance imaging: a deep learning perspective
    Aim: Up to date many successful attempts to identify various types of lesions with machine learning (ML) were made, however, the recognition of Alzheimer’s disease (AD) from brain images and inter [...] Read more.
    Karolina Armonaite ... Luigi Laura
    Published: June 30, 2023 Explor Neuroprot Ther. 2023;3:139–150
    DOI: https://doi.org/10.37349/ent.2023.00043
    Open Access
    Looking at the periphery—new hypothesis to look for new targets for Alzheimer’s disease therapy
    Currently, the predominant targets for the treatment of Alzheimer’s disease (AD) are the main components of the two pathological structures: senile plaques (composed of amyloid beta peptide aggreg [...] Read more.
    Jesús Avila ... Félix Hernández
    Published: June 30, 2023 Explor Neuroprot Ther. 2023;3:151–163
    DOI: https://doi.org/10.37349/ent.2023.00044
    Times Cited: 0
    Open Access
    Can chronic therapeutic drug use by the elderly affect Alzheimer’s disease risk and rate of progression?
    There is no approved drug capable of halting the progression of the most prevalent neurodegenerative disorders, namely Alzheimer's disease (AD) and Parkinson's disease (PD).  [...] Read more.
    Rafael Franco, Joan Serrano-Marín
    Published: February 27, 2023 Explor Neuroprot Ther 2023;3:8–23
    DOI: https://doi.org/10.37349/ent.2023.00035